DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Tocilizumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Schweiz) AG. In 2013, its product was firstly approved in China and its indication is RA.

Tocilizumab was approved in China as the first biological agent for the treatment of sJIA in 2016, was included in China's medical insurance in 2019, and was approved in China for the third indication of CRS in 2020. By 2020, Tocilizumab has registered a number of studies in China, and its indications include RA, sJIA, and CRS. By 2020, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese Tocilizumab market.

The market research shows that the sales of Tocilizumab have had an increasing trend from 2016 to 2020. Since Tocilizumab was approved for the new indication sJIA in 2016, the sales increase in 2017 with 21.30% of the growth rate from 2016 to 2017. With the inclusion of Tocilizumab in China's medical insurance in 2019 and the approval of its new indications in China in 2020, the sales in 2020 increased evidently, from CNY20.07 million in 2019 to CNY41.72 million in 2020. The growth rate is about 107.89%. The CAGR of Tocilizumab was 16.25% from 2016 to 2020.

According to the market research, as the Tocilizumab market will expand from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are carrying out relevant clinical trials. After Tocilizumab biosimilars are approved in the market, its manufacturers will gradually increase, the market will continue to grow and the price will decline.

These situations will lead to an increase in Tocilizumab sales value and sales volume. In addition, Tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of approved indications in China has upside potential. It can be predicted that with the increase of indications, its sales will continue to grow with the expansion of the market in the future.

Topics Covered:

• The impact of COVID-19 on China's Tocilizumab market
• Sales value of China's Tocilizumab 2016-2020
• Competitive landscape of China's Tocilizumab market
• Prices of Tocilizumab in China
• Prices of Tocilizumab in China by regions and manufacturers
• Analysis of factors affecting the development of China's Tocilizumab market
• Prospect of China's Tocilizumab market from 2021 to 2025

Key Topics Covered:

1 Relevant Concept of Tocilizumab

1.1 Indications for Tocilizumab

1.2 Development of Tocilizumab in China

1.3 Governmental Approval of Tocilizumab in China

1.4 The Impact of COVID-19 on Tocilizumab sales in China

2 Sales of Tocilizumab in China, 2016-2020

2.1 Sales Value of Tocilizumab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Tocilizumab

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Tocilizumab by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Tocilizumab Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Tocilizumab Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Roche Pharma (Schweiz) AG

3.2.1 Enterprise Profile

3.2.2 Sales of ACTEMRA (Roche Pharma (Schweiz) AG's Tocilizumab) in China

4 Prices of Tocilizumab for Different Manufacturers in China, 2020-2021

4.1 Roche Pharma (Schweiz) AG (ACTEMRA)

4.2 Others

5 Prospect of Chinese Tocilizumab Market, 2021-2025

5.1 Influential Factors of Chinese Tocilizumab Market Development

5.1.1 The Impact of COVID-19 on Chinese Tocilizumab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

• Roche Pharma (Schweiz) AG

For more information about this report visit https://www.researchandmarkets.com/r/vtn37h

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900